Literature DB >> 24744022

Update on treatments for dystonia.

D Cristopher Bragg1, Nutan Sharma.   

Abstract

Oral medication, botulinum toxin injections, and deep brain stimulation are the current mainstays of treatment for dystonia. In addition, physical and other supportive therapies may help prevent further complications (eg, contractures) and improve function. This review discusses evidence-based medical treatment of dystonia with an emphasis on recent advances in treatment. We will also review the current treatment approaches and suggest ways in which these therapies can be applied to individuals with dystonia.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24744022      PMCID： PMC4477531          DOI： 10.1007/s11910-014-0454-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  29 in total

1.  Utility of an EMG mapping study in treating cervical dystonia.

Authors:  J A Van Gerpen; J Y Matsumoto; J E Ahlskog; D M Maraganore; P G McManis
Journal:  Muscle Nerve       Date:  2000-11       Impact factor: 3.217

2.  Clinical and polymyographic investigation of spasmodic torticollis.

Authors:  G Deuschl; F Heinen; B Kleedorfer; M Wagner; C H Lücking; W Poewe
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

3.  Intrathecal baclofen for generalized dystonia.

Authors:  A L Albright; M J Barry; D H Shafton; S S Ferson
Journal:  Dev Med Child Neurol       Date:  2001-10       Impact factor: 5.449

4.  Setting realistic expectations for DBS in dystonia.

Authors:  Michael S Okun; Kelly D Foote
Journal:  Lancet Neurol       Date:  2012-11-01       Impact factor: 44.182

Review 5.  History, applications, and mechanisms of deep brain stimulation.

Authors:  Svjetlana Miocinovic; Suvarchala Somayajula; Shilpa Chitnis; Jerrold L Vitek
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

6.  Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy.

Authors:  D Dressler
Journal:  Eur J Neurol       Date:  2000-11       Impact factor: 6.089

7.  Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation.

Authors:  René Reese; Doreen Gruber; Thomas Schoenecker; Hansjörg Bäzner; Christian Blahak; H Holger Capelle; Daniela Falk; Jan Herzog; Marcus O Pinsker; Gerd H Schneider; Christoph Schrader; Günther Deuschl; Hubertus M Mehdorn; Andreas Kupsch; Jens Volkmann; Joachim K Krauss
Journal:  Mov Disord       Date:  2011-02-10       Impact factor: 10.338

8.  Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders.

Authors:  Christopher Kenney; Christine Hunter; Joseph Jankovic
Journal:  Mov Disord       Date:  2007-01-15       Impact factor: 10.338

9.  Pallidal deep-brain stimulation in primary generalized or segmental dystonia.

Authors:  Andreas Kupsch; Reiner Benecke; Jörg Müller; Thomas Trottenberg; Gerd-Helge Schneider; Werner Poewe; Wilhelm Eisner; Alexander Wolters; Jan-Uwe Müller; Günther Deuschl; Marcus O Pinsker; Inger Marie Skogseid; Geir Ketil Roeste; Juliane Vollmer-Haase; Angela Brentrup; Martin Krause; Volker Tronnier; Alfons Schnitzler; Jürgen Voges; Guido Nikkhah; Jan Vesper; Markus Naumann; Jens Volkmann
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

Review 10.  Medical treatment of dystonia.

Authors:  Joseph Jankovic
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338
View more
  2 in total

1.  Acrylamide inhibits nerve sprouting induced by botulinum toxin type A.

Authors:  Hong Jiang; Yi Xiang; Xingyue Hu; Huaying Cai
Journal:  Neural Regen Res       Date:  2014-08-15       Impact factor: 5.135

2.  Multitarget Multiscale Simulation for Pharmacological Treatment of Dystonia in Motor Cortex.

Authors:  Samuel A Neymotin; Salvador Dura-Bernal; Peter Lakatos; Terence D Sanger; William W Lytton
Journal:  Front Pharmacol       Date:  2016-06-14       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.